Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 16/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938750 | 0.96 | MLYCD (0.60) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL6843778 | 0.95 | MLYCD (0.64) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL2938693 | 0.80 | MLYCD (0.63) | MLYCDNR1H2NR1H3 | |
| SCHEMBL6843613 | 0.77 | MLYCD (0.71) | MLYCDLMNASMN1; SMN2NR1H2NR1H3 | |
| SCHEMBL6521921 | 0.76 | HTR2C (0.43) | MLYCD | |
| Hydrochloric Acid SCHEMBL3394146 | 0.75 | HTR2C (0.44) | MLYCD | |
| SCHEMBL6521913 | 0.75 | KDM2B (0.46) | MLYCD | |
| SCHEMBL4988361 | 0.75 | MLYCD (1.00) | MLYCD | |
| Hydrochloric Acid SCHEMBL3395885 | 0.74 | KDM2B (0.45) | MLYCD | |
| SCHEMBL3422810 | 0.74 | KDM2B (0.45) | MLYCDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087627-A1 | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | ME2, PC, ACACA | MLYCD 6/4885LMNA 1268/4885SMN1; SMN2 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.